How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

789 results for

Lidocaine Patch

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Pharmacodynamics and Pharmacokinetics of Lidocaine in a Rodent Model of Diabetic Neuropathy. (PubMed)

diabetes.We performed a series of sciatic nerve block experiments in 25 Zucker Diabetic Fatty rats aged 20 weeks with a neuropathy component confirmed by neurophysiology and control rats. We determined in vivo the minimum local anesthetic dose of lidocaine for sciatic nerve block. To investigate the pharmacokinetic hypothesis, we determined concentrations of radiolabeled (C) lidocaine up to 90 min after administration. Last, dorsal root ganglia were excised for patch clamp measurements of sodium channel (...) Pharmacodynamics and Pharmacokinetics of Lidocaine in a Rodent Model of Diabetic Neuropathy. Clinical and experimental data show that peripheral nerve blocks last longer in the presence of diabetic neuropathy. This may occur because diabetic nerve fibers are more sensitive to local anesthetics or because the local anesthetic concentration decreases more slowly in the diabetic nerve. The aim of this study was to investigate both hypotheses in a rodent model of neuropathy secondary to type 2

2017 Anesthesiology

62. Pharmacokinetics of Lidocaine in Healthy Adults

provided by (Responsible Party): Nicole K Brogden, University of Iowa Study Details Study Description Go to Brief Summary: The study to be performed will utilize already FDA-approved marketed products in healthy adults for the purpose to generate data for establishing rate of drug delivery of Lidoderm® topical patch (manufactured by Endo Pharmaceuticals) and the lidocaine 5% patch (manufactured by Mylan Pharmaceuticals) in healthy adults, and to ensure the safety of individuals utilizing these types (...) of products. Condition or disease Intervention/treatment Phase Healthy Drug: Lidocaine patch 5% Drug: Lidocaine Hydrochloride Drug: Lidoderm 5 % Topical Patch Phase 4 Detailed Description: Topical drug delivery systems in the form of patches are convenient, attractive, and easy to use. Lidocaine is a very popular patch available on the United States market today. Accurate determination of the rate and extent of drug release and absorption is crucial to ensure the safety of individuals using

2017 Clinical Trials

63. PK and DPK of Lidocaine Dermal Products

Study Description Go to Brief Summary: This is a bioequivalence study to compare lidocaine release between a brand name and generic skin patches in healthy adults. Condition or disease Intervention/treatment Phase Heat Effect Drug: Lidocaine patch Early Phase 1 Detailed Description: This research study is intended to determine the effect of heat on lidocaine patches. This study will use lidocaine patches (brand name and generic patches) that have been approved by the Food and Drug Administration (...) : January 10, 2019 Estimated Study Completion Date : June 30, 2019 Resource links provided by the National Library of Medicine available for: Arms and Interventions Go to Arm Intervention/treatment name brand patch name brand lidocaine patch Drug: Lidocaine patch lidocaine patch Other Name: skin patch generic patch generic lidocaine patch Drug: Lidocaine patch lidocaine patch Other Name: skin patch name brand patch-early name brand lidocaine patch-early Drug: Lidocaine patch lidocaine patch Other Name

2017 Clinical Trials

64. Lidocaine suppresses glioma cell proliferation by inhibiting TRPM7 channels (PubMed)

cell growth and proliferation. As local anesthetic lidocaine has been shown to inhibit TRPM7 currents, we hypothesize that lidocaine may suppress glioma cell proliferation through TRPM7 channel inhibition.TRPM7 currents were recorded in rat C6 glioma cells using the whole cell patch clamp technique. Cell growth and proliferation were assessed under microscopic examination and biochemical assays.Lidocaine inhibits TRPM7-like currents in a dose-dependent and reversible manner. At 1 and 3 mM (...) Lidocaine suppresses glioma cell proliferation by inhibiting TRPM7 channels Malignant glioma is the most common brain cancer with devastating prognosis. Recurrence of malignant glioma following surgery is very common with few preventive and therapeutic options. Novel targets and therapeutic agents are constantly sought for better outcome. Our previous study established that inhibition of transient receptor potential melastatin 7 (TRPM7) channels resulted in significant decrease of human glioma

Full Text available with Trip Pro

2017 International journal of physiology, pathophysiology and pharmacology

65. The Efficacy of Systemic Lidocaine in the Management of Chronic Pain: A Literature Review (PubMed)

pain.To prepare this narrative review, we performed an in depth literature review using the PubMed searching engine. We extracted all relevant articles published in English, up to April 2016.Lidocaine, administered as transdermal patch or intravenous lidocaine, is a safe and effective modality in the treatment of post-herpetic neuralgia (PHN), complex regional pain syndrome, as well and for prevention of chronic pain. It may be effective in the management of neuropathic pain syndromes, chronic pain (...) , post-operative pain, and refractory cancer pain.Intravenous lidocaine and lidocaine patch are effective and safe for the treatment of several chronic or neuropathic pain syndromes. The use of lidocaine during surgery could prevent the development of some chronic post-surgical pain syndromes.

Full Text available with Trip Pro

2017 Anesthesiology and pain medicine

66. Lidocaine patch (5%) in treatment of persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled, crossover trial. (PubMed)

Lidocaine patch (5%) in treatment of persistent inguinal postherniorrhaphy pain: a randomized, double-blind, placebo-controlled, crossover trial. Evidence-based pharmacological treatment options for patients with persistent inguinal postherniorrhaphy pain are lacking.Twenty-one male patients, with severe, unilateral, persistent inguinal postherniorrhaphy pain, participated in a randomized, double-blind, placebo-controlled crossover trial, receiving lidocaine patch (5%) and placebo patch (...) and after each treatment period. The primary outcome was change in pain intensity assessed as the difference in summed pain intensity differences between lidocaine and placebo patch treatments.There was no difference in summed pain intensity differences between lidocaine and placebo patch treatments in all patients (mean difference 6.2% [95% CI = -6.6 to 18.9%]; P = 0.33) or in the two subgroups (+/- thermal "hyposensitivity"). The quantitative sensory testing (n = 21) demonstrated an increased pressure

Full Text available with Trip Pro

2013 Anesthesiology

67. Utility of the heated lidocaine/tetracaine patch in the treatment of pain associated with shoulder impingement syndrome: a pilot study. (PubMed)

Utility of the heated lidocaine/tetracaine patch in the treatment of pain associated with shoulder impingement syndrome: a pilot study. Pain control is an important first step in the treatment of shoulder impingement syndrome (SIS) because fear of pain must be removed as an obstacle to participation in an appropriate physical therapy program.Adult patients with SIS-associated pain of at least 2 weeks' duration and who had an average pain score of ≥4 on the zero- to ten-point Numeric Pain Rating (...) Scale were eligible to enroll in this 2-week pilot study. Patients were treated with the heated lidocaine/tetracaine (70 mg/70 mg) patch (HLT patch) placed over the site of shoulder tenderness each morning and evening for a period of 2 to 4 hours. Average and worst pain during the previous 24 hours and shoulder range of motion were assessed at baseline and on Day 14. Results were expressed as change and percent change from baseline to Day 14. This pilot study was not powered for rigorous statistical

Full Text available with Trip Pro

2013 International journal of general medicine

68. Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain

Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain Etodolac-Lidocaine Patch in the Treatment of Acute Low Back Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Etodolac-Lidocaine Patch (...) Description Go to Brief Summary: The purpose of this study is to evaluate efficacy, tolerability and safety of Etoreat®(Etodolac-Lidocaine Topical Patch) in the treatment of acute low back pain (LBP). Condition or disease Intervention/treatment Phase Low Back Pain Drug: Etoreat®(Etodolac-Lidocaine Topical Patch) Drug: Placebo Phase 3 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Actual Enrollment : 232 participants Allocation: Randomized Intervention

2013 Clinical Trials

69. Effectiveness of a heated lidocaine/tetracaine topical patch for pain associated with myofascial trigger points: results of an open-label pilot study. (PubMed)

Effectiveness of a heated lidocaine/tetracaine topical patch for pain associated with myofascial trigger points: results of an open-label pilot study. Evaluate potential usefulness of a heated lidocaine/tetracaine topical patch for treatment for pain associated with myofascial trigger points (MTPs).Depth and duration of analgesia when patch is used as indicated, on intact skin to provide local dermal analgesia for superficial venous access and dermatologic procedures, suggest utility in relief (...) after stopping treatment, average pain intensity was 5.0 ± 2.04; treatment benefit was maintained in 8 (40%) patients. The most common adverse event was erythema.The heated lidocaine/tetracaine patch has potential utility as a noninvasive pharmacologic approach for managing MTP pain. Further studies are warranted.© 2012 The Authors Pain Practice © 2012 World Institute of Pain.

2013 Pain Practice

70. Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain

neuropathic pain even though using of this patch for a population of cancer patients has never been demonstrated so far in a prospective study. The present prospective study proposes to evaluate the qutenza efficacy in peripheric neuropathic pain in cancer patients. Condition or disease Intervention/treatment Phase Neuropathic Pain Drug: Qutenza Phase 2 Detailed Description: Drugs for neuropathic pains are generally represented by antidepressants, anti-epileptics, opioids, lidocaine patch. However (...) Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain Clinical Trial Assessing the Efficacy of Capsaicin Patch (Qutenza®) in Cancer Patients With Neuropathic Pain - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies

2017 Clinical Trials

71. Lidocaine and Benzocaine are Equally Effective in Reducing Pain from Injection of Needles

. #2) Carr/2001 Two groups of 20 healthy adults (40 subjects total), 21-70 years old Randomized Controlled Trial Key results Licocaine Delivery System (LDS) transoral patch topical anesthesia was more effective in reducing pain scores (Verbal Pain Scale, VPS, 0-4; and Visual Analog Scale, VAS, 1-100) from needle sticks than benzocaine gel (BGP) or placebo (P #3) Rosivack/1990 60 healthy adults, 26-60 years old Randomized Controlled Trial Key results Both lidocaine and benzocaine were significantly (...) . The use of topical lidocaine or benzocaine in gel or ointment form is feasible in most dental settings, whereas the use of a transoral lidocaine patch may be less feasible in some dental settings. Utilization of topical anesthesia is very likely to be accepted by the average patient as the benefits of reducing needle injection pain and reducing discomfort/anxiety during dental procedures outweigh the harms/risks of experiencing a temporary unpleasant taste or temporary unpleasant sensation

2012 UTHSCSA Dental School CAT Library

72. Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers. (PubMed)

Lidocaine patch (5%) produces a selective, but incomplete block of Aδ and C fibers. Topical lidocaine (5%) leads to sufficient pain relief in only 29%-80% of treated patients, presumably by small-fiber block. The reasons for nonresponse are unclear; it may be due to different underlying pain mechanisms or partly insufficient anesthetic effect. Using quantitative sensory testing (QST) following the protocol of the DFNS (German Research Network on Neuropathic Pain), this study aims to assess (...) the type and extent of somatosensory changes after lidocaine application in healthy volunteers. Twenty-six healthy volunteers underwent QST on the volar forearm, including thermal and mechanical detection and pain thresholds, twice before (for baseline retest reliability) and once after 6-hour simultaneous application with lidocaine patch 5% and contralateral placebo in a double-blinded manner. Pre and post differences of QST parameters were analyzed by paired t-test (Bonferroni-corrected alpha 0.0023

2012 Pain

73. Efficacy and safety of a lidocaine/tetracaine medicated patch or peel for dermatologic procedures: a meta-analysis. (PubMed)

Efficacy and safety of a lidocaine/tetracaine medicated patch or peel for dermatologic procedures: a meta-analysis. To justify the use of the lidocaine/tetracaine medicated patch or peel as a preventive treatment for reducing pain and discomfort in adults and children. We reviewed randomized controlled trials (RCTs) to evaluate the efficacy and safety of the lidocaine/tetracaine medicated patch or peel compared with placebo.Ten RCTs (574 patients) were included in this systemic review. Relevant (...) studies were identified through searches of MEDLINE, SCOPUS and the Cochrane database library. The outcome was the adequacy of cutaneous anesthesia reflected in the patient's assessment of pain intensity during minor dermatologic procedures and adverse effects after application of the lidocaine/tetracaine medicated patch or peel versus placebo.The efficacy of the lidocaine/tetracaine patch or peel was consistently very significantly beneficial 30 or 60 minutes after the application compared to placebo

Full Text available with Trip Pro

2012 Korean journal of anesthesiology

74. Lidocaine/tetracaine patch (Rapydan) for topical anaesthesia before arterial access: a double-blind, randomized trial. (PubMed)

Lidocaine/tetracaine patch (Rapydan) for topical anaesthesia before arterial access: a double-blind, randomized trial. Arterial catheterization is painful and is associated with patient stress and anxiety. Analgesia is usually provided by subcutaneous injection of local anaesthetic. An alternative is topical anaesthesia, such as Rapydan which is a novel topical anaesthetic patch containing 70 mg each of lidocaine and tetracaine. We therefore tested the hypothesis that Rapydan patch analgesia (...) is non-inferior to subcutaneous local anaesthetic.Ninety patients undergoing elective major cardiac surgery were included in this prospective, double-blind clinical trial. Patients were randomly assigned to receive either a lidocaine/tetracaine patch, followed by subcutaneous injection 0.5 ml of normal saline solution, or placebo patch with subsequent subcutaneous injection of 0.5 ml of lidocaine 1%. Pain during arterial catheterization using 100-mm-long visual analogue scale (VAS) was the primary

Full Text available with Trip Pro

2012 British Journal of Anaesthesia

75. Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. (PubMed)

Lidocaine patch (5%) is no more potent than placebo in treating chronic back pain when tested in a randomised double blind placebo controlled brain imaging study. The 5% Lidocaine patch is used for treating chronic neuropathic pain conditions such as chronic back pain (CBP), diabetic neuropathy and complex regional pain syndrome, but is effective in a variable proportion of patients. Our lab has reported that this treatment reduces CBP intensity and associated brain activations when tested (...) in an open labelled preliminary study. Notably, effectiveness of the 5% Lidocaine patch has not been tested against placebo for treating CBP. In this study, effectiveness of the 5% Lidocaine patch was compared with placebo in 30 CBP patients in a randomised double-blind study where 15 patients received 5% Lidocaine patches and the remaining patients received placebo patches. Functional MRI was used to identify brain activity for fluctuations of spontaneous pain, at baseline and at two time points after

Full Text available with Trip Pro

2012 Molecular pain

76. Effects of application durations and heat on the pharmacokinetic properties of drug delivered by a lidocaine/tetracaine patch: a randomized, open-label, controlled study in healthy volunteers. (PubMed)

Effects of application durations and heat on the pharmacokinetic properties of drug delivered by a lidocaine/tetracaine patch: a randomized, open-label, controlled study in healthy volunteers. The lidocaine/tetracaine heated patch is typically applied to the skin for 20 to 30 minutes to provide local dermal analgesia prior to venous access or minor dermatologic procedures. The potential exists for the use of multiple heated patches for longer application times, but the pharmacokinetic (...) properties and tolerability of these multiple and/or longer applications have not been assessed.The aim of this study was to assess the effects of heat and application time on the pharmacokinetic properties and tolerability of the patch after the application of 4 lidocaine/tetracaine (70/70 mg) heated patches applied at the same time in healthy volunteers for up to 12 hours.In this randomized, open-labeled, controlled study, healthy subjects underwent 4 treatment periods (2-, 4-, or 12-hour application

2012 Clinical therapeutics

77. Treatment for postoperative wound pain in gynecologic laparoscopic surgery: topical lidocaine patches. (PubMed)

Treatment for postoperative wound pain in gynecologic laparoscopic surgery: topical lidocaine patches. This article reports our early experience with the use of lidocaine patches for pain control in the immediate postoperative period after laparoscopic gynecologic surgery.A prospective, double-blind, placebo-controlled clinical trial was conducted on 40 patients undergoing a gynecologic laparoscopy who were randomized to receive either topical patches of 700 mg of lidocaine (n=20) or placebo (...) patches (n=20). The patch was divided evenly into four smaller patches, which were applied at the four port sites and changed every 12 hours for 36 hours after surgery. Postoperative pain was evaluated using the visual analog scale (VAS) score and the Prince Henry and 5-point verbal rating pain scale (VRS), and the analgesic requirement was also evaluated at 1, 6, 12, 24, and 36 hours after surgery.The VAS score for wound pain was lower in the lidocaine patch group at 1 and 6 hours after surgery than

2012 Journal of laparoendoscopic & advanced surgical techniques. Part A

78. Therapeutic effects of lidocaine patch on myofascial pain syndrome of the upper trapezius: a randomized, double-blind, placebo-controlled study. (PubMed)

Therapeutic effects of lidocaine patch on myofascial pain syndrome of the upper trapezius: a randomized, double-blind, placebo-controlled study. The aim of this study was to compare topical 5% lidocaine patch with placebo patch in the treatment of myofascial pain syndrome of the upper trapezius.In this prospective, randomized, double-blind, placebo-controlled study, 60 participants were randomly assigned, placing 31 subjects in the 5% lidocaine patch group and 29 subjects in the placebo patch (...) of the participants did not differ at baseline. Pain intensity assessed by the VRS decreased at day 7 in both the lidocaine patch and placebo patch groups. There was no significant difference between the two groups in the VRS, the Pressure Pain Threshold, the ranges of motion, and the Neck Disability Index. At day 14, the experimental group continued to improve in the VRS (1.06), but the pain of the placebo group aggravated (VRS, 1.5). The difference is significant (P = 0.03). In addition, the Neck Disability

2012 American journal of physical medicine & rehabilitation / Association of Academic Physiatrists

79. Availability of a 5% lidocaine patch used prophylactically for venipuncture- or injection-related pain in children. (PubMed)

Availability of a 5% lidocaine patch used prophylactically for venipuncture- or injection-related pain in children. Venipuncture- or injection-related pain is still major problem during anesthetic induction in children. This study was designed to determine the availability of a 5% lidocaine patch used prophylactically for venipuncture- or injection-related pain during the induction of anesthesia.In a randomized, double-blind study, 72 pediatric patients were allocated to one of two groups (...) : pretreatment with a 5% lidocaine patch (Lidoderm(®), Endo Pharmaceuticals, Chadds Ford, PA, USA) (group A) or pretreatment with a placebo patch (group B). Pain severity was evaluated on the Faces, Legs, Activity, Cry, and Consolability Scale (FLACC) during venipuncture, and a 4-point scale during the injection of rocuronium.The FLACC score during venipuncture was significantly lower for group A than group B (p < 0.001). There was no significant difference in the grades of the 4-point scale observed during

2012 Journal of anesthesia

80. Corticosteroid and Lidocain Injections for Tennis Elbow

Corticosteroid and Lidocain Injections for Tennis Elbow Corticosteroid and Lidocain Injections for Tennis Elbow - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Corticosteroid and Lidocain Injections (...) Hospital Study Details Study Description Go to Brief Summary: The investigators hypothesized that lidocain injection is as effective as corticosteroid injection in management of tennis elbow, and if so, it may replace corticosteroid injection in the management of tennis elbow. Condition or disease Intervention/treatment Phase Tennis Elbow Lateral Epicondylitis Drug: Corticosteroid Drug: Lidocaine Not Applicable Detailed Description: Lateral epicondylitis or tennis elbow is a tendinopathy of the common

2016 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>